Atlas Trials

A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Clinical trial NCT01130337 · COMPLETED

Trial details

NCT number
NCT01130337
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2010-07-01
Primary completion
2014-06-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.